AOD-9604
From PeptideSciences101, the open peptide reference. · Last updated: October 7, 2025
This article is a stub. A peer-reviewed deep-dive is in preparation. Help contribute to expand it.
…
Overview
Modified fragment of growth hormone designed specifically for fat loss without affecting blood sugar or growth.
Reported benefits
Fat metabolism, body composition improvement, no impact on blood sugar, cartilage repair
Protocols & dosing
Typical dosage: 300 mcg (daily).
Detailed dosing protocols have not yet been catalogued.
FDA & legal status
AOD-9604 is not currently FDA-approved for any indication. It is generally classified as a research compound. Regulatory status varies by country.
| Country | Status |
|---|---|
| United States | Research use only |
| United Kingdom | Prescription-only / not licensed |
| Canada | Prescription-only / Schedule F if licensed |
| Australia | TGA-scheduled |
Vendor information
PeptideSciences101 does not endorse vendors. For transparency metrics and third-party testing notes, see the vendor directory.
Side effects & safety
Reported side effects: Minimal side effects reported
References
No external sources have been catalogued for this article yet.
Related peptides
- CagriSema — Combination therapy
- Dulaglutide — Weekly GLP-1 (Trulicity)
- Fragment 176-191 — HGH fragment for fat loss
- Leptin — Satiety hormone
- Liraglutide — FDA-approved GLP-1 for weight loss
- MOTS-c — Mitochondrial optimization
Categories: Weight Management & Metabolic